Research programme: recombinant human insulin - Adocia

Drug Profile

Research programme: recombinant human insulin - Adocia

Alternative Names: BioChaperone Lispro U300; Combo insulin fast and slow - Adocia; insulin glulisine/insulin aspart - Adocia; Ultra-concentrated prandial insulin - Adocia

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in France (Parenteral, Injection)
  • 19 Dec 2014 Adocia and Eli Lilly enter into a worldwide licensing collaboration for co-development of an ultra-fast acting insulin for the treatment of type 1 and type 2 diabetes mellitus. The agreement also covers Adocia's concentrated formulation of an ultra-fast acting insulin analogue (BioChaperone® Lispro U300)
  • 04 Sep 2012 Research programme: recombinant human insulin - Adocia is available for licensing as of 04 Sep 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top